These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 26747896

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
    Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, Elkahloun AG, Valk PJ, Döhner K, Neilly MB, Bullinger L, Delwel R, Löwenberg B, Liu PP, Morgan R, Rowley JD, Yuan CS, Chen J.
    Blood; 2013 Feb 21; 121(8):1422-31. PubMed ID: 23264595
    [Abstract] [Full Text] [Related]

  • 4. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J.
    Proc Natl Acad Sci U S A; 2012 Nov 20; 109(47):19397-402. PubMed ID: 23132946
    [Abstract] [Full Text] [Related]

  • 5. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A, Jakobsen JS, Ohlsson E, Rapin N, Waage J, Billing M, Bullinger L, Karlsson S, Porse BT.
    Leukemia; 2015 May 20; 29(5):1018-31. PubMed ID: 25349154
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG, Pasillas MP, Kamps MP.
    Mol Cell Biol; 2006 May 20; 26(10):3902-16. PubMed ID: 16648484
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, Downing JR.
    Leukemia; 2007 Sep 20; 21(9):2000-9. PubMed ID: 17597811
    [Abstract] [Full Text] [Related]

  • 10. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.
    Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE.
    Leukemia; 1999 May 20; 13(5):687-98. PubMed ID: 10374871
    [Abstract] [Full Text] [Related]

  • 11. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.
    Garcia-Cuellar MP, Steger J, Füller E, Hetzner K, Slany RK.
    Haematologica; 2015 Jul 20; 100(7):905-13. PubMed ID: 25911551
    [Abstract] [Full Text] [Related]

  • 12. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.
    Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, Frampton J, Slany RK.
    Blood; 2006 Jul 01; 108(1):297-304. PubMed ID: 16507773
    [Abstract] [Full Text] [Related]

  • 13. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
    So CW, Karsunky H, Wong P, Weissman IL, Cleary ML.
    Blood; 2004 Apr 15; 103(8):3192-9. PubMed ID: 15070702
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
    Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.
    Nat Commun; 2012 Feb 21; 3():688. PubMed ID: 22353710
    [Abstract] [Full Text] [Related]

  • 16. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL.
    Cancer Res; 2007 Aug 01; 67(15):7275-83. PubMed ID: 17671196
    [Abstract] [Full Text] [Related]

  • 17. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
    Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E.
    Oncogene; 2001 Feb 15; 20(7):874-8. PubMed ID: 11314021
    [Abstract] [Full Text] [Related]

  • 18. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML.
    Genes Dev; 2007 Nov 01; 21(21):2762-74. PubMed ID: 17942707
    [Abstract] [Full Text] [Related]

  • 19. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
    Mian YA, Zeleznik-Le NJ.
    Leuk Res; 2016 Jul 01; 46():51-60. PubMed ID: 27123834
    [Abstract] [Full Text] [Related]

  • 20. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
    Zeisig BB, Milne T, García-Cuéllar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK.
    Mol Cell Biol; 2004 Jan 01; 24(2):617-28. PubMed ID: 14701735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.